Autoimmunity after liver transplantation: a frequent event but a rare clinical problem

Antonella Foschi, Claudio Zavaglia, Diana Fanti, Chiara Mazzarelli, Giovanni Perricone, Marcello Vangeli, Raffaella Viganò, L Belli

Clinical Transplantation · 2014 · 13 citations · 18 references

Concepts

TL;DR

Autoantibodies are frequently detected after liver transplantation, yet their clinical significance remains unclear. The study sought to determine autoantibody prevalence before and up to five years after transplantation, identify potential predictors, and examine their relationship with graft dysfunction. Researchers retrospectively analyzed 92 consecutive liver transplant recipients with prospectively stored sera, measuring autoantibodies by immunofluorescence. Autoantibody prevalence rose markedly post‑transplant (64 % vs 27 % at ≥1:80, 35.9 % vs 8.7 % at ≥1:160), was unrelated to donor/recipient factors or immunosuppression, was higher in patients with graft dysfunction at high titers, and no de novo autoimmune hepatitis occurred, indicating that autoantibodies are common but likely nonspecific markers of liver injury.

Abstract

Autoantibodies are frequently detected after liver transplantation (LT), but their role is unclear. This study was designed to address three points: autoantibody prevalence pre-LT and over time up to five yr after LT, identification of possible predictors of autoantibody formation, and correlation between autoantibodies and graft dysfunction. To these aims, we retrospectively evaluated 92 consecutive LT recipients for whom prospectively stored frozen sera were available for autoantibodies assessment by immunofluorescence. The overall autoantibody prevalence resulted significantly higher after LT than before LT (64% vs. 27%, p < 0.001 and 35.9% vs. 8.7%, p < 0.001 considering cutoff titer of ≥ 1:80 and ≥ 1:160, respectively). Recipient gender, donor age and gender, and indication for LT and main immunosuppressant (cyclosporine vs. tacrolimus) were not associated with the presence of autoantibodies. Patients with graft dysfunction had a significantly higher autoantibody prevalence irrespective of the etiology of liver injury as compared to those patients with persistently normal liver biochemistry, but only for cutoff titers ≥ 1:160 (p = 0.004). No cases of de novo autoimmune hepatitis were observed. In conclusion, autoantibodies are very frequently detected after LT also at high titers and their association with graft dysfunction likely represents an aspecific indicator of liver injury.

References

18